Marker Therapeutics (NASDAQ: MRKR) shares APOLLO Phase 1 study update

Rhea-AI Filing Summary

Marker Therapeutics, Inc. filed a Form 8-K to share new information about its Phase 1 APOLLO study. On August 26, 2025, the company issued a press release describing progress and clinical observations from this study and furnished it as Exhibit 99.1. Marker also updated its corporate presentation, made available on its website and attached as Exhibit 99.2, and prepared a webcast presentation on the APOLLO study results, attached as Exhibit 99.3. The company states that this information is being furnished under Regulation FD and is not deemed filed for liability purposes under the federal securities laws.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001094038 0001094038 2025-08-26 2025-08-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

August 26, 2025

Date of Report (Date of earliest event reported)

MARKER THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-37939	45-4497941
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

2450 Holcombe Blvd, TMC Partners Office 1.311 Houston, Texas		77021
(Address of principal executive offices)		(Zip Code)

(713) 400-6400

Registrant’s telephone number, including area code

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		MRKR		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01. Regulation FD Disclosure.

On August 26, 2025, Marker Therapeutics, Inc. (the “Company”) issued a press release announcing the progress and clinical observations from the Company’s Phase 1 APOLLO study. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

In addition, on August 26, 2025, the Company updated its corporate presentation, which is available through the Company’s website and a copy of which is attached hereto as Exhibit 99.2 to this Current Report on Form 8-K. The Company will also host a webcast discussing the results from the Company’s APOLLO study. The webcast presentation is attached hereto as Exhibit 99.3.

The information in this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1, 99.2 and 99.3) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press release, dated August 26, 2025.
99.2		Corporate Presentation, dated August 26, 2025.
99.3		Webcast Presentation, dated August 26, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Marker Therapeutics, Inc.
Dated: August 26, 2025	By:	/s/ Juan Vera
		Juan Vera
		President and Chief Executive Officer

FAQ

What did Marker Therapeutics (MRKR) disclose in this Form 8-K?

Marker Therapeutics reported that it issued a press release, updated its corporate presentation, and prepared a webcast presentation describing progress and clinical observations from its Phase 1 APOLLO study.

What is the focus of Marker Therapeutics APOLLO study mentioned for MRKR?

The filing states that the company provided an update on the Phase 1 APOLLO study, including progress and clinical observations, through a press release and related presentations.

Which exhibits are attached to Marker Therapeutics 8-K about the APOLLO study?

The 8-K includes Exhibit 99.1 (press release dated August 26, 2025), Exhibit 99.2 (corporate presentation dated August 26, 2025), Exhibit 99.3 (webcast presentation), and Exhibit 104 (cover page interactive data file).

Is the APOLLO study information in this MRKR 8-K considered filed or furnished?

The company specifies that the information in Item 7.01, including Exhibits 99.1, 99.2, and 99.3, is being furnished and is not deemed filed under Section 18 of the Exchange Act or Sections 11 and 12(a)(2) of the Securities Act.

Does Marker Therapeutics mention a webcast related to the APOLLO Phase 1 study?

Yes. Marker states it will host a webcast discussing results from the APOLLO study, and the webcast presentation is attached as Exhibit 99.3 to the 8-K.

When did Marker Therapeutics issue the APOLLO study press release and update its presentation?

Both the press release and the updated corporate presentation are dated August 26, 2025, the same date as the event reported in the Form 8-K.